

August 12, 2021

**Acurx Pharmaceuticals**

# **Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021**

**Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.**

STATEN ISLAND, N.Y., Aug. 12, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P. Luci, President & CEO, will present at the Emerging Growth Conference as follows:

Date: Wednesday, August 18, 2021

Time: 11:15 a.m. Eastern Time

Webcast: [https://goto.webcasts.com/starthere.jsp?ei=1486517&tp\\_key=3bd9735fe4&sti=acxp](https://goto.webcasts.com/starthere.jsp?ei=1486517&tp_key=3bd9735fe4&sti=acxp)

This live, interactive online event will provide current stockholders and the investment community the opportunity to interact with David P. Luci. As time permits, Mr. Luci may be able to respond to questions from participants.

The presentations will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company's website at [www.acurxpharmaceuticals.com](http://www.acurxpharmaceuticals.com), under the Investors section.

## **About Acurx Pharmaceuticals, Inc.**

Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase III C enzyme and its R&D preclinical pipeline includes antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE) and Penicillin-Resistant Streptococcus pneumoniae (PRSP).

To learn more about Acurx Pharmaceuticals and its product pipeline, please visit [www.acurxpharma.com](http://www.acurxpharma.com).

## **Investor Contact:**

Acurx Pharmaceuticals, Inc.

David P. Luci, President & CEO

Tel: 917-533-1469

Email: [davidluci@acurxpharma.com](mailto:davidluci@acurxpharma.com)

View original content: <https://www.prnewswire.com/news-releases/acurx-pharmaceuticals->

[to-present-at-the-emerging-growth-conference-on-august-18-2021-301353864.html](https://www.sec.gov/edgar/disclosure/realtime/etf/etf/20210818/301353864.html)

SOURCE Acurx Pharmaceuticals, Inc.